Human IGFBP-3 Recombinant
$70.00 – $2,700.00
| accession | P17936 |
| Source | Optimized DNA sequence encoding HumanIGFBP-3 mature chain fused to an N-terminal His tag was expressed in CHO Cells. |
| Molecular weight | Native human IGFBP-3, generated by the proteolytic removal of the signal peptide and propeptide,the molecule has a calculated molecular mass of approximately 28 kDa. RecombinantIGFBP-3 is a monomer protein consisting of 269 amino acid residue subunits, migrates as an approximately28 kDa protein under non-reducing and reducing conditions in SDS-PAGE. |
| Purity | >95%, as determined by SDS-PAGE and HPLC |
| Biological Activity | The ED(50) was determined by the ability toinhibit IGF-II induced proliferation of MCF-7 and was foundto be≤ 0.2 μg/ml in the presence of 15 ng/ml human IGF-II. |
| Protein Sequence | |
| Endotoxin | Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg(1EU/µg). |
| Presentation | Recombinant IGFBP3was lyophilized from a 0.2 μm filtered PBS solution. |
| Reconstitution | A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers. |
| Storage | The lyophilized protein is stable for at least 2 years from date of receipt at -20° C. Upon reconstitution, this cytokine can be stored in working aliquots at 2° - 8° C for one month, or at -20° C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles. |
| Usage | This cytokine product is for research purposes only.It may not be used for therapeutics or diagnostic purposes. |
| Interactor | P05019 IGF1_HUMAN |
| Interactor | P01344 IGF2_HUMAN |
